Rankings
▼
Calendar
CGEM Q3 2024 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CGEM
Cullinan Therapeutics, Inc.
$894M
Q3 2024 Earnings
Healthcare
Medical - Pharmaceuticals
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$49M
Net Income
-$41M
EPS (Diluted)
$-0.70
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$34M
Free Cash Flow
-$34M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$653M
Total Liabilities
$25M
Stockholders' Equity
$628M
Cash & Equivalents
$102M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$49M
-$45M
-8.0%
Net Income
-$41M
-$39M
-3.5%
← FY 2024
All Quarters
Q4 2024 →